Enicepatide

Enicepatide is Roche's dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes, the lead asset Roche picked up via the $2.7B Carmot Therapeutics acquisition in December 2023 [1]. The molecule hits the same two receptors as Lilly's tirzepatide (Mounjaro/Zepbound) and is dosed once-weekly subcutaneously. Phase 2 data in obese adults without diabetes showed approximately 18.8% placebo-adjusted weight loss at 24 weeks per Roche's July 2024 topline disclosure, a number that put Roche in the conversation with Lilly and Novo on efficacy [2]. Two Phase 3 trials are now recruiting under Hoffmann-La Roche as sponsor per company disclosure: one in obesity (n≈2000) and one in obesity with T2D (n≈1600), both with a 72-week percent-change-in-body-weight endpoint, for a total Phase 3 commitment of approximately 3,600 patients [3][4]. For Roche, this is the ticket into the largest pharma category of the decade. The GLP-1 class hit roughly $50B in 2024 and analysts project $100B+ by 2030, with Lilly and Novo holding nearly all of it today. Enicepatide is Roche's only credible obesity entry, and the strategic case for the Carmot deal hinges on this single molecule clearing Phase 3.

Novel compound, never approved anywhere. The Phase 3 program launched in 2025 with two actively recruiting trials per Roche disclosure: NCT07351045 in obesity (n≈2000) and NCT07351058 in obesity plus T2D (n≈1600) [3][4]. These NCT identifiers reflect Roche's announced program; specific protocol details should be re-confirmed against the current ClinicalTrials.gov record before any time-sensitive decision. Sponsor on both is Hoffmann-La Roche. The Phase 2 obesity trial (NCT06525935, n=469) completed and produced the headline 18.8% placebo-adjusted weight loss at week 24 [5][2]. A separate Phase 2 in obesity with T2D (NCT06628362, n=360) is active but no longer recruiting, with a 36-week body weight endpoint that should inform Phase 3 dose selection [6]. No FDA breakthrough therapy, fast track, or orphan designations have been disclosed publicly, and none would be expected for a non-first-in-class obesity drug. Roche has not given specific timeline guidance beyond calling this a priority asset on earnings calls. Working back from the 72-week Phase 3 primary endpoint in trials that began enrolling in 2025, primary readouts realistically land in 2027-2028, with BLA filings in 2028-2029 if the data holds. That puts approval roughly 4 years behind tirzepatide in obesity. On exclusivity: composition-of-matter patent filings for CT-388 trace to the Carmot era, plausibly providing patent protection into the late 2030s, plus 5 years of US NCE exclusivity from approval. Exact filing dates were not independently verified for this writeup and investors should pull the published patent family before modeling peak-sales windows. Speed matters less than the absolute efficacy number Roche posts.

Two incretin hormones, two receptors, one molecule. GLP-1 (glucagon-like peptide 1) is a gut hormone released after meals that tells your pancreas to release insulin, slows stomach emptying so you feel full longer, and acts on brain circuits in the hypothalamus to reduce hunger. GIP (glucose-dependent insulinotropic polypeptide) is its less-famous cousin: peripherally, it also boosts insulin after meals and helps fat tissue process incoming calories without the pathological storage seen in insulin-resistant obesity. Critically, GIP receptors are also expressed in the brain - including in the hypothalamus - where GIP agonism drives appetite suppression through a pathway distinct from GLP-1, which is why combining both receptors produces greater weight loss than either alone rather than a merely additive effect. Individually, each hormone is useful. Together they're synergistic, which is the bet Lilly proved with tirzepatide. Enicepatide is engineered to activate both GLP1R and GIPR with a once-weekly subcutaneous dosing profile suitable for chronic use [7]. The mechanism is the most validated target combination in modern metabolic disease. Tirzepatide 15mg hit approximately 20.9% absolute mean weight reduction at week 72 in SURMOUNT-1 (placebo arm ~3.1%, placebo-subtracted ~17.8%) [8], and beat semaglutide head-to-head on A1c in SURPASS-2 [9]. Retatrutide, Lilly's triple agonist that adds glucagon receptor activation, pushed the Phase 2 ceiling to roughly 24% weight loss at 48 weeks [10]. What's still unsettled across the class: the optimal GLP-1 to GIP activation ratio, biased signaling differences between molecules, and whether GIP receptor agonism or antagonism is the right strategy - multiple programs are pursuing GIP antagonism as an alternative bet.

Two Phase 3 trials per Roche disclosure, both placebo-controlled, both with a primary endpoint of percent change in body weight at week 72 [3][4]. NCT07351045 enrolls obesity or overweight patients without T2D, target ~2000. NCT07351058 enrolls obesity or overweight with T2D, target ~1600. The Phase 2 T2D study (NCT06628362) uses a 36-week body weight primary with n=360 across dose arms, a dose-finding design [6]. Roche has not publicly broken out the specific dose arm(s) carried from Phase 2 into Phase 3; investors should expect at least two active doses to mirror the tirzepatide titration ladder, with final dose selection pending the Phase 2 T2D readout. Trial design in the Phase 3 program is conventional for the indication. Placebo comparator is the FDA standard for obesity registration and is required for the label. Critically, neither Phase 3 trial includes an active comparator arm against tirzepatide or semaglutide. That's a defensible regulatory choice but a commercial weakness: Roche will be relying on cross-trial comparisons to position against incumbents, and cross-trial comparisons in obesity are noisy. SURMOUNT-1 used different titration schedules, different baseline BMI strata, and different rescue medication rules than what Roche has disclosed. Enrollment pace is the leading indicator to watch. Tirzepatide trials enrolled quickly because the field was open. Roche is recruiting into a market where investigators and patients have multiple effective options already, including off-label tirzepatide. Site activation rates and screening-to-randomization ratios in 2026 will tell the story before any efficacy number lands.

Our model gives this drug a 22% chance of eventually being approved. That estimate starts from the historical approval rate for Phase 2 drugs in this area - about 35% - then adjusts based on ten facts about the trial and sponsor. The number is helped by more secondary endpoints than usual, larger-than-typical enrollment for this phase, and the sponsor's strong track record of getting drugs approved, and held back by weak earlier-phase results. The remaining facts were close to average for this stage, so they didn't move the estimate much.

Efficacy bar is the dominant risk. SURMOUNT-1 reported tirzepatide 15mg at approximately 20.9% absolute weight reduction at week 72, or roughly 17.8% placebo-subtracted [8]; retatrutide Phase 2 hit approximately 24% absolute weight loss at 48 weeks [10]. If Enicepatide lands at 16-18% placebo-adjusted at 72 weeks in Phase 3, the trial is a statistical win versus placebo but a commercial loss against Lilly. The Phase 2 number of 18.8% placebo-adjusted at 24 weeks is encouraging because tirzepatide 15mg at the same timepoint in SURMOUNT-1 showed approximately 13-15% placebo-adjusted (estimated from publicly available time-course data, since 24 weeks is not a SURMOUNT-1 primary timepoint) [2][8], but the 72-week number is what matters and 24-week cross-trial reads are noisy because of differing titration paces. Class-typical GI side effects (nausea, vomiting, diarrhea) drive dropout in incretin trials; Phase 2 discontinuation rates will be scrutinized when full data publishes. Safety. Incretin agonists carry post-marketing signals for pancreatitis, gallbladder events, and ileus across the class. Recent FDA review of semaglutide for suicidal ideation (ultimately not confirmed) showed validated mechanisms still face regulatory friction at scale. Execution and manufacturing. Producing injectable peptides at obesity-market scale is hard. Novo and Lilly both hit supply constraints in 2023-2024. Roche has biologics manufacturing depth through Genentech but does not have the dedicated peptide synthesis footprint that Novo and Lilly built over the past decade; Roche has not publicly committed to in-house peptide capacity at scale for enicepatide, which implies meaningful CMO reliance at launch. Commercial. Even at competitive efficacy, payer formularies are now locked in around tirzepatide and semaglutide, with prior authorization and step therapy in place. Roche needs superior efficacy, materially better tolerability, or a meaningfully different dosing profile to displace. Phase 2 data does not yet show any of those. Format risk. Enicepatide is subcutaneous-only. Lilly's oral orforglipron is in Phase 3 and Novo has oral GLP-1 programs in development. If oral incretins reach the market with credible efficacy in the late 2020s, an SC-only molecule with no oral follow-on has a narrower long-term moat. Roche has not publicly disclosed an oral enicepatide program.

Worth watching. Roche has put real capital behind this asset ($2.7B for Carmot upfront, plus milestones and R&D burn) [1], and Phase 2 was strong enough to commit to Phase 3 in both obesity and T2D with a combined enrollment of approximately 3,600 patients. The signal that matters: 72-week placebo-adjusted weight loss in NCT07351045. If it lands at roughly 20% or higher (placebo-adjusted), Roche has a credible second-in-class drug with a path to meaningful share in a $100B+ market by 2030. If it comes in at 14-16% placebo-adjusted, it's a salvageable product but a clear number-three behind tirzepatide and semaglutide. Check back at three moments: (1) any Phase 2 T2D readout from NCT06628362 in late 2026 or 2027, which will indicate whether glycemic control matches tirzepatide; (2) Phase 3 enrollment commentary in Roche quarterly calls through 2026, since site activation rates predict whether 72-week data lands on the expected 2027-2028 timeline; (3) retatrutide Phase 3 readouts in 2026, which will reset the efficacy ceiling. The $5-10B peak-sales projection assumes a 2028-2029 approval, US NCE exclusivity through ~2033-2034, and composition-of-matter patent coverage running into the late 2030s - the latter is plausible based on Carmot-era filing windows but should be verified against the published patent family before any investment thesis is locked. Connect to the company: Roche's pharma division ran approximately $50B in 2024 and faces biosimilar erosion on Herceptin and Avastin plus deceleration in Tecentriq. Obesity is the most credible large-scale growth driver they have added in years. A successful Enicepatide launch could add $5-10B at peak. A failed launch leaves Roche dependent on oncology and diagnostics to grow, and validates the bear case on the Carmot acquisition price.